IVCC has welcomed the WHO Pre-Qualification of Bayer’s Fludora™ Fusion, combining different modes of action, as another major step forward in malaria control and insecticide resistance management.

IVCC supported the development of this new indoor residual spray (IRS) product in field trials where the product was tested against various resistant mosquito strains and on different relevant surface types. The data generated demonstrated that Fludora™ Fusion provides robust and consistent results, matching the needs of malaria control programs across Africa.

Nick Hamon, CEO of IVCC said: “We were pleased to have been able to support part of the Fludora™ Fusion trial program and to see this milestone achieved. New vector control tools are desperately needed to combat resistance and this is another positive addition to the toolbox.”

IVCC’s David McGuire who, with other consortium partners PMI, Abt Associates and PATH, leads the $65.1m Unitaid funded NgenIRS initiative, added: “Fludora™ Fusion will be a powerful and timely addition to the range of new indoor residual spray products implementing partners can use across sub-Saharan Africa.Following the successful deployment of Syngenta’s Actellic® 300 CS and Sumitomo’s SumiShield® we now have greater choice of new generation IRS products that can support sub-national rotation of insecticides, a major weapon against the threat of insecticide resistance. The introduction of more products from different manufacturers has also created a competitive environment for third generation IRS that is driving down prices to affordable levels for malaria control programs and their donor partners.

Dr. Jacqueline M. Applegate, Head of the Environmental Science business unit at Bayer added: “We are very proud to have achieved WHO Pre-Qualification for Fludora™ Fusion; it reflects our long-term commitment towards supporting the elimination of vector-borne diseases. It is a clear example of our focus on applying science to advance life – malaria control programs will now have access to an additional safe, efficient and cost-effective solution to protect the millions at risk from the disease.”

For further information, please contact:

Chris Larkin
Head of Communications and External Relations
IVCC
Phone: +44 151 702 9371
Mobile: +44 7712 402498
Email: christopher.larkin@IVCC.com(link sends e-mail)

About IVCC

IVCC is the only product development partnership (PDP) working in vector control. Established in 2005, IVCC works with stakeholders to facilitate the development of novel and improved public health insecticides and formulations and provides information tools to enable their effective use. IVCC’s vision is simply to save lives, protect health and increase prosperity by preventing insect-borne diseases. IVCC is funded by The Bill & Melinda Gates Foundation, UKaid, USAID, Unitaid, the Global Fund, the Australian Government and The Swiss Agency for Development and Cooperation.

About Bayer

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen.

The 67th Annual Meeting of the American Society of Tropical Medicine and Hygiene

Members of the NgenIRS project, along with a few thousand colleagues from around the world, met in New Orleans, LA for five days to share recent findings from world-class research on tropical medicine and hygiene, including malaria. Molly Robertson, Evidence lead for the NgenIRS project at PATH, along with Larry Slutsker, Director of Malaria and Neglected Tropical Diseases at PATH, co-chaired a symposium on indoor residual spraying (IRS) and drug-based malaria control. Symposium presenters reviewed observational evidence and modeling showing the benefits of combining IRS for malaria vector control with drug-based interventions, including mass drug administration (MDA) and seasonal malaria chemoprevention (SMC), for malaria parasite control. Diadier Diallo of MEASURE Evaluation presented research on IRS and SMC in the Segou Region of Mali showing that there was a 39 percent reduction in all-ages malaria incidence in areas that received both IRS and SMC compared to a 16 percent reduction in SMC areas and a 28% reduction in IRS areas. Other symposium presenters included Thom Eisele from Tulane University, Dorothy Echodu from Pilgrim Africa, and Ellie Sherrard-Smith from Imperial College.

NgenIRS partners from PATH also presented updated analyses on the cluster randomised control trial in Mopeia, Mozambique; the impact of introducing IRS in Mopti Region, Mali; and the reintroduction of IRS in Northern and Upper East Regions, Ghana. In Mozambique, preliminary results from active cohort surveillance based on spray status have shown a 17-month cumulative rate ratio of .81 (.77-.94). Interim analysis of case data from routine health systems reflect the same trends seen in infection data from the active cohort—a significant reduction in malaria incidence of approximately 19.4% to 25% in IRS vs. non-IRS clusters. In Ghana, preliminary analyses show clear correlations in time and space with indoor residual spraying of a 3GIRS product and reduced incidence of confirmed malaria cases from routine surveillance systems in the north of Ghana, where pyrethroid resistance is widely reported. Finally, in Mali, after introducing IRS into 4 districts of Mopti in 2017, rapid diagnostic testing (RDT)-confirmed malaria rates fell 37% compared to similar unsprayed districts. And after suspending IRS in Segou District in 2017, RDT+ confirmed malaria rates rose 125% compared to similar unsprayed districts. Final in-depth analyses on all of the aforementioned work will be forthcoming in 2019.

Symposium co-chairs and speakers show up in costume during the October 31st ASTMH session on combining IRS and drug-based interventions.

IVCC is to lead a consortium of partners on a ground-breaking project funded by Unitaid and the Global Fund to bring to market new versions of insecticide-treated bed nets to fight malaria-carrying mosquitoes that have become resistant to older insecticides. It is hoped that the nets will provide a stronger line of defence against malaria for millions of people.

The New Nets Project, signed in Geneva yesterday will pilot long-lasting insecticidal bed nets treated with new insecticide combinations in sub-Saharan African countries hardest hit by malaria.

The Global Fund and Unitaid will each contribute US$33 million to the four-year project. The coalition, consisting of PATH, Population Services International (PSI) / Alliance for Malaria Prevention (AMP), London School of Hygiene and Tropical Medicine (LSHTM), with support from Imperial College London, Liverpool School of Tropical Medicine, and Tulane University, will run between 2018 and 2022.

The project will build the evidence needed to allow WHO to consider making new policy around the use of these nets and will also assess their cost-effectiveness under pilot conditions.

The production volumes procured for the pilots will help the project to negotiate significant price reductions. These reductions are needed to make the new nets a sustainable choice for countries looking for the best value for money in controlling malaria.

Nick Hamon, CEO of IVCC said; “The continued success and impact on lives saved of the NGenIRS project means that IVCC is well positioned, with its project partners, to demonstrate the public health value of new dual active ingredient bed nets and deliver radically new solutions to combat the growing threat of insecticide resistance which is prevalent across malaria endemic countries.

Unitaid’s Executive Director Lelio Marmora added: “Working with partners such as the Global Fund, we can leverage the effect of our innovations, such as new insecticides and new insecticide-treated nets,” said “Together we can make a powerful impact against malaria.”

Mosquito nets provide a physical barrier against mosquitoes and treating the nets with insecticide makes them lethal for mosquitoes that land on them. One of the most effective means of preventing malaria is sleeping under a long-lasting insecticidal net.

Mosquitoes’ resistance to insecticides threatens to undermine progress against malaria. Although the number of new malaria cases has fallen dramatically over the past 15 years, progress has recently stalled. According to the World Health Organization, there were 216 million cases of malaria worldwide in 2016, 5 million more cases than the year before.

A child dies of malaria every two minutes, although the disease is preventable and curable.

“By investing in insecticide-treated nets and other tools, the Global Fund partnership has greatly reduced the burden of malaria,” said Peter Sands, Executive Director of the Global Fund. “This project is a step toward accelerating impact by embracing innovation – with the ultimate goal of malaria elimination.”

The New Nets Project will support the WHO’s malaria goals, which aim by 2030 to reduce malaria cases and deaths by 90 percent, eliminate the disease in at least 35 countries and prevent a resurgence in countries that are malaria-free.

IVCC is leading another Unitaid-funded initiative, the US$65 million NgenIRS project, which is ushering in new long-lasting indoor residual insecticide sprays to replace less-effective older chemistries and formulations. Unitaid’s work against malaria extends to the Asia Pacific Region, where it is collaborating with the Asia Pacific Leaders Malaria Alliance (APLMA) on the Vector Control Platform for Asia Pacific (VCAP), a collaborative platform to improve access to new vector control tools.

The Innovative Vector Control Consortium (IVCC) has been awarded a four-year A$18.75m grant by the Australian Government to help eradicate malaria and other deadly mosquito-borne diseases from the Indo-Pacific region.

As part of the Australian Government’s landmark Health Security Initiative which aims to improve the health security of developing countries who bear 99% of the world’s malaria burden, the Indo-Pacific Centre for Health Security will support IVCC in its development and dissemination of innovative vector control solutions to address the very real health threat of mosquito borne diseases in the Indo-Pacific region.

Nick Hamon, CEO of IVCC said: “IVCC has supported the development of vector control products since its inception in 2005.  This has led to the release of game-changing tools to mitigate insecticide resistance build up. Together with the Australian Government and partners we look forward to leveraging and adapting this robust pipeline of innovative vector control solutions to maximise the opportunity to save lives in the Indo-Pacific region and help prevent the spread of vector borne diseases.”

For further information, please contact:

Chris Larkin
Head of Communications and External Relations
Phone: +44 151 702 9371
Mobile: +44 7712 402498
Email: christopher.larkin@IVCC.com